Approval · Notice of Compliance 38173 · 2026
TEVA-SUMATRIPTAN: Notice of Compliance 38173
Issued August 26, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38173
- Date
- August 26, 2026
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph (to align with CRP approved PM)
- Canadian reference product
- IMITREX AND IMITREX DF (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-SUMATRIPTAN | Not yet assigned | — |
| TEVA-SUMATRIPTAN DF | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 100 MG per TAB
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB